Press Releases Events & Presentations Press Releases Year None202420232022202120202019201820172016201520142013201220112010 Dec 19, 2024 Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs View HTML PDF Version Nov 07, 2024 Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates View HTML PDF Version Sep 23, 2024 Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 View HTML PDF Version Aug 08, 2024 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates View HTML PDF Version Jul 15, 2024 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop View HTML PDF Version Jun 18, 2024 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jun 17, 2024 Assembly Biosciences Announces $12.6 Million in Equity Financings View HTML PDF Version Jun 10, 2024 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 View HTML PDF Version Jun 05, 2024 Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024 View HTML PDF Version May 22, 2024 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024 View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Press Releases Year None202420232022202120202019201820172016201520142013201220112010 Dec 19, 2024 Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs View HTML PDF Version Nov 07, 2024 Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates View HTML PDF Version Sep 23, 2024 Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 View HTML PDF Version Aug 08, 2024 Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates View HTML PDF Version Jul 15, 2024 Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop View HTML PDF Version Jun 18, 2024 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection View HTML PDF Version Jun 17, 2024 Assembly Biosciences Announces $12.6 Million in Equity Financings View HTML PDF Version Jun 10, 2024 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 View HTML PDF Version Jun 05, 2024 Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024 View HTML PDF Version May 22, 2024 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024 View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
